Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 28:13:877682.
doi: 10.3389/fimmu.2022.877682. eCollection 2022.

Efficient derivation of chimeric-antigen receptor-modified TSCM cells

Affiliations

Efficient derivation of chimeric-antigen receptor-modified TSCM cells

Emiko Kranz et al. Front Immunol. .

Abstract

Chimeric-antigen receptor (CAR) T-cell immunotherapy employs autologous-T cells modified with an antigen-specific CAR. Current CAR-T manufacturing processes tend to yield products dominated by effector T cells and relatively small proportions of long-lived memory T cells. Those few cells are a so-called stem cell memory T (TSCM) subset, which express naïve T-cell markers and are capable of self-renewal and oligopotent differentiation into effector phenotypes. Increasing the proportion of this subset may lead to more effective therapies by improving CAR-T persistence; however, there is currently no standardized protocol for the effective generation of CAR-TSCM cells. Here we present a simplified protocol enabling efficient derivation of gene-modified TSCM cells: Stimulation of naïve CD8+ T cells with only soluble anti-CD3 antibody and culture with IL-7 and IL-15 was sufficient for derivation of CD8+ T cells harboring TSCM phenotypes and oligopotent capabilities. These in-vitro expanded TSCM cells were engineered with CARs targeting the HIV-1 envelope protein as well as the CD19 molecule and demonstrated effector activity both in vitro and in a xenograft mouse model. This simple protocol for the derivation of CAR-TSCM cells may facilitate improved adoptive immunotherapy.

Keywords: CAR; HIV-1; TSCM; adoptive immunotherapy; gene therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Derivation of gene-marked CD8+ T cells harboring TSCM-surface phenotype under different stimulation conditions. Freshly isolated human PBMCs were separated for CD8+ TN cells using an EasySep™ Human Naïve CD8+ T Cell Enrichment kit. Cells were stimulated for 2 days with the condition as in (A), followed by transduction with lentiviral vector encoding EGFP as a transduction marker. Cells were cultured for an additional 12 days in the presence of 5 ng/mL of IL-7 and IL-15, and cell-surface marker profiles were analyzed by flow cytometry. (A) Summary for derivation of TSCM cells procedure. (B) Flow cytometry analyses of CD8+ TN cells genetically marked by EGFP with no antibody stimulation. (C) % positivity of EGFP-marked cells (Top bars) and fold changes in cell number following 14 days of culture (Bottom bars). (D) Flow cytometry analyses of EGFP-engineered CD8+ TN cells. All experiments were repeated at least three times. Error bars in (C) show the standard deviation of a data set. One representative experiment is shown for (B, D).
Figure 2
Figure 2
Prolonged culture increases % population of CD8+ T cells harboring TSCM-surface phenotype with maintaining oligopotency Freshly isolated CD8+ TN cells were transduced with lentiviral vector encoding EGFP following stimulation with various antibody conditions shown in Figure 1A . The cells were cultured for an additional 12 days (A, Day14) or 26 days (B, Day 28) in the presence of 5 ng/mL of IL-7 and IL-15. A half million of cells in A was co-stimulated by 0.5 μg/mL anti-CD3 and 2.0 μg/mL anti-CD28 antibodies and further cultures for 14 days (C, 2nd stimulation). Cells were staining for CD45RA, CD45RO, CCR7, CD62L, CD95 and CD122, and surface marker of EGFP-marked cells were analyzed by flow cytometry. Each cell number of EGFP-marked cells with TN, TSCM, TCM, TEM, and TEMRA phenotypes was plotted. Experiments were repeated three times. Error bars show the standard deviation of a data set.
Figure 3
Figure 3
Induced differentiation of Triple-CD4ζ modified CD8+ T cells harboring TSCM-surface phenotype with anti-CD3 and CD28 co-stimulation. (A) Triple-CD4ζ or EGFP-modified CD8+ T cells were co-stimulated with 0.5 µg/mL of anti-CD3 and 2.0 µg/mL of CD28 antibodies for 2 days (2nd stimulation) at day14 post-1st stimulation. The cells were further cultured for an additional 12 days in the presence of 5 ng/mL of IL-7 and IL-15. Cell-surface profiles of gene-marked CD8+ T cells were analyzed by flow cytometry. Each cell number of EGFP- or Triple-CD4ζ-marked cells with TN, TSCM, TCM, TEM, and TEMRA phenotypes was plotted with or without 2nd stimulation. Experiments were repeated three times. Error bars show the standard deviation of a data set. (B) The cells were plated at 5 x 104 cells/100 μL in a 96-well plate. The same number of TagBFP-labeled Jurkat cells (ΔKS, non-target control) and mCherry-labeled Jurkat cells constitutively expressing HIV-1HXBC2 envelope protein (HXBC2, target cells) were added to the wells and incubated for 4 or 16 hours. Total numbers of each population were determined by MACSQuant, and relative cytotoxicity of target cells relative to non-target cells was determined. -: unstimulated, +: 2nd stimulated. Experiments were repeated three times. Error bars show the standard deviation of a data set. Cytotoxicity assays were performed in biological triplicate.
Figure 4
Figure 4
Triple-CD4ζ CAR-modified CD8+ T cells harboring TSCM-surface phenotype eliminate tumor cells expressing HIV-1 envelope proteins in a xenograft mouse model. Two million mStrawberry-labeled CD19+ TF228.1.16 cells expressing envelope protein from HIV-1BH10 or mCherry-labeled Jurkat cells expressing envelope protein from HIV-1HXBC2 (HXBC2), were mixed with Matrigel at a 1:1 ratio and subcutaneously engrafted to the left or right hind limbs of NOD-SCID mice from ventral side, respectively (n = 4). Freshly isolated CD8+ TN cells were stimulated for 2 days with 0.5 µg/mL of anti-CD3 antibody in T-cell medium, followed by transduction with a lentiviral vector encoding either Triple-CD4ζ or FMC63-IgG4ζ. Following 26 days of culture in the presence of 5 ng/mL of IL-7 and IL-15, cells corresponding to 5 x 105 CAR-modified cells were intravenously injected via the retro-orbital vein on day 14 post-engraftment of TF228.1.16 and HXBC2. Biofluorescence images (A) and the weight of xenograft tumors (B) were obtained on day 42 post-engraftment (on day 28 post-transplant of CAR cells). (B) Blue or orange bars: average weight of xenograft tumors from TF228.1.16 (left limb, blue bars) or HXBC2 (right limb, orange bars) on day 42 post-engraftment. Experiments were repeated three times with similar results. Two representative animals from each group were shown.

Similar articles

Cited by

References

    1. Wilkie S, van Schalkwyk MC, Hobbs S, Davies DM, van der Stegen SJ, Pereira AC, et al. . Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol (2012) 32:1059–70. doi: 10.1007/s10875-012-9689-9 - DOI - PubMed
    1. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest (2007) 117:1466–76. doi: 10.1172/JCI32446 - DOI - PMC - PubMed
    1. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol (2006) 6:383–93. doi: 10.1038/nri1842 - DOI - PMC - PubMed
    1. Gill S, Maus MV, Porter DL. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev (2016) 30:157–67. doi: 10.1016/j.blre.2015.10.003 - DOI - PubMed
    1. Lindner SE, Johnson SM, Brown CE, Wang LD. Chimeric antigen receptor signaling: Functional consequences and design implications. Sci Adv (2020) 6:eaaz3223. doi: 10.1126/sciadv.aaz3223 - DOI - PMC - PubMed

Publication types